|
Medical Expenditure Panel Survey (MEPS): Experiences with Cancer Survivorship Supplement (MEPS CSAQ)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC
|
NCI, OD/DPCPSI/OBSSR
|
The National Cancer Institute (NCI) has collaborated with CDC, AHRQ, and other organizations to provide supplemental funding for the Medical Expenditure Panel Survey (MEPS) to improve the quality of data for estimating the cancer survivorship burden in the United States. Using responses to the National Health Interview Survey (NHIS) question about ever receiving a cancer diagnoses, households with cancer survivors were oversampled for selection in this MEPS Supplement. The increased sample of cancer survivors will improve national estimates of the burden of cancer. Additionally, this collaborative group developed a targeted questionnaire and associated database to further understand the burden of cancer, its treatment and impact on access to health care, the ability to work and participate in usual activities, health insurance, and quality of care. The collaborative group is developing an updated version of this questionnaire, with additional questions on employment impacts of cancer and social determinants of health, for future administration.
|
|
Medical Imaging & Data Resource Center (MIDRC)
|
Resource Development
|
FDA
|
NIBIB, NCI, CC, NCATS, NHLBI, NLM
|
MIDRC curates medical images and develops AI-ready data and AI/ML algorithms for helping with the clinical management of COVID-19 patients and the pandemic in general. As of this date, over 105,000 highly curated AI-ready COVID image-sets are already available for public access and investigation, about 200,000 more image-sets are in the pipeline, and 24 algorithms are under development. MIDRC-sponsored challenges have enhanced algorithm development. The contract was extended to a third year (ongoing) to include study patients who have suffered from longer-term symptoms of COVID. MIDRC has expanded interoperability with other NIH ICs (e.g., NCATS, NHBLI) and Argonne National Lab (DOE). An internal NIH advisory board monitors MIDRC progress along with NIBIB. MIDRC is now a national resource of curated medical images of COVID patients, ready to be used to develop clinically useful AI applications. Medical facilities in 24 US states contribute information and interact with MIDRC through the American Association of Medical Physicists, the American College of Radiology, and the Radiological Association of America.
|
|
Memorandum of Understanding (MoU) between FDA/Center for Drug Evaluation and Research (CDER) and NIH/NINDS
|
Other
|
FDA
|
NINDS
|
This MoU provides a mechanism for addressing cross-cutting issues related to drug evaluation and research for neurological disorders, from bench science to clinical studies and the Food and Drug Administration (FDA) approval.
|
|
Memorandum of Understanding (MOU) between the FDA Center for Devices and Radiological Health and NIH/NINDS
|
Other
|
FDA
|
NINDS
|
This MOU provides a mechanism for addressing cross-cutting issues related to the development of devices for neurological disorders, from bench science to clinical studies and the Food and Drug Administration (FDA) approval.
|
|
Memorandum of Understanding (MOU) between the FDA/Center for Biologics Evaluation and Research (FDA/CBER) and NIH/NINDS
|
Other
|
FDA
|
NINDS
|
This Memorandum of Understanding (MOU) provides a mechanism for addressing cross-cutting issues related to therapy development for neurological disorders, from bench science to clinical trials and the Food and Drug Administration (FDA) approval and licensure.
|
|
Microphysiological Systems for Drug Efficacy and Toxicity Testing (Tissue Chip for Drug Screening)
|
Research Initiative
|
FDA, ASPR
|
NCATS, NCI, NEI, NHLBI, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIGMS, NINDS, NINR, OD/DPCPSI/ORWH, OD/DPCPSI/OSC
|
The Microphysiological systems (MPS) initiative aims to develop 3-D human tissue chips that accurately model the structure and function of human organs, such as the lung, liver, and heart. Researchers are currently using these models to predict whether a candidate drug, vaccine, or biologic agent is safe or toxic in humans in a faster and more cost-effective way than current methods. More than 30 percent of promising medications have failed in human clinical trials because they are determined to be toxic despite promising pre-clinical studies in animal models. These organs-on-chips will also enable scientists to predict more accurately how effective a therapeutic candidate would be in clinical studies. To help streamline the therapeutic development pipeline, NIH, in collaboration with the US Food and Drug Administration (FDA) and the Innovation and Quality (IQ) Consortium of pharmaceutical companies, is leading this initiative to improve the process for predicting whether drugs will be safe and effective in humans. In an effort to overcome some clinical trial challenges, Clinical Trials on a Chip is supporting the development of tissue chips to inform clinical trial design for both common and rare diseases; support the planning and execution of clinical trials; assist in patient stratification; help identify reliable clinical trial endpoints; and ultimately develop tools for more informative and efficient clinical trials for both common and rare diseases. Another program, the Tissue Chips in Space initiative, is creating tissue- and organ-on-chip platforms that can be sent to the ISS National Lab so that scientists can better understand the role of microgravity on human health and diseases and translate those findings to improve human health on Earth. Current efforts aim to bring tissue chips towards FDA regulatory qualification as drug development tools by establishing Translational Centers for MPS.
|
|
Mind Your Risks
|
Public Education Campaign
|
CDC, CMS
|
NINDS
|
The Mind Your Risks campaign is designed to create awareness and action about the fact that risk factors for stroke, particularly hypertension, may be linked to cognitive impairment and dementia.
|
|
Molecular Approaches To Antiviral Development For Viral Hepatitis and Other Viral Diseases
|
Research Initiative
|
IHS
|
NIDDK
|
Molecular Approaches To Antiviral Development For Viral Hepatitis and Other Viral Diseases
|
|
Molecular approaches to understand vector-host and vector-pathogen interactions
|
Research Initiative
|
FDA
|
NIAID
|
Molecular approaches to understand vector-host and vector-pathogen interactions
|
|
Molecular Immunohematology in Ethiopian Sub-populations
|
Research Initiative
|
FDA
|
CC
|
Molecular Immunohematology in Ethiopian Sub-populations
|